Clinical management of advanced gastric cancer: The role of new molecular drugs

World Journal of Gastroenterology

Volumn 20, Issue 40, 2014, Pages 14537-14558

  De Vita, Ferdinando ^a   Di Martino, Natale ^a   Fabozzi, Alessio ^a   Laterza, Maria Maddalena ^a   Ventriglia, Jole ^a   Savastano, Beatrice ^a   Petrillo, Angelica ^a   Gambardella, Valentina ^a   Sforza, Vincenzo ^a   Marano, Luigi ^a   Auricchio, Annamaria ^a   Galizia, Gennaro ^a   Ciardiello, Fortunato ^a   Orditura, Michele ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Advanced gastric cancer; Gastric cancer; Gastrointestinal cancer; Monoclonal antibodies; Targeted therapy; Tyrosine kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; APATINIB; BEVACIZUMAB; CEDIRANIB; CETUXIMAB; CRIZOTINIB; ERLOTINIB; EVEROLIMUS; FORETINIB; GEFITINIB; LAPATINIB; MATUZUMAB; NIMOTUZUMAB; ONARTUZUMAB; PANITUMUMAB; PERTUZUMAB; PONATINIB; RAMUCIRUMAB; RILOTUMUMAB; SORAFENIB; SUNITINIB; TELATINIB; TIVANTINIB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DRUG EFFICACY; DRUG TARGETING; ESOPHAGUS CARCINOMA; HUMAN; INTRACELLULAR SIGNALING; MULTICENTER STUDY (TOPIC); ONCOGENE C KIT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH CANCER; SURGICAL TECHNIQUE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84910642961     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i40.14537     Document Type: Review

References (190)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30 [PMID: 23335087 DOI: 10.3322/caac.21166]
3. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730 [PMID: 11547741]
4. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20 [PMID: 16822992]
5. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Königsrainer A, Budach W, Wilke H. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27: 851-856 [PMID: 19139439 DOI: 10.1200/JCO.2008.17.0506]
6. Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29: 1715-1721 [PMID: 21444866 DOI: 10.1200/JCO.2010.33.0597]
7. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010; (3): CD004064 [PMID: 20238327 DOI: 10.1002/14651858.CD004064.pub3]
8. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49 [PMID: 14320675]
9. You WC, Blot WJ, Li JY, Chang YS, Jin ML, Kneller R, Zhang L, Han ZX, Zeng XR, Liu WD. Precancerous gastric lesions in a population at high risk of stomach cancer. Cancer Res 1993; 53: 1317-1321 [PMID: 8443811]
10. Correa P, Haenszel W, Cuello C, Zavala D, Fontham E, Zarama G, Tannenbaum S, Collazos T, Ruiz B. Gastric precancerous process in a high risk population: cross-sectional studies. Cancer Res 1990; 50: 4731-4736 [PMID: 2369747]
11. Peek RM, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002; 2: 28-37 [PMID: 11902583]
12. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-789 [PMID: 11556297]
13. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006; 12: 354-362 [PMID: 16489633]
14. Shah MA, Khanin R, Tang L, Janjigian YY, Klimstra DS, Gerdes H, Kelsen DP. Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res 2011; 17: 2693-2701 [PMID: 21430069 DOI: 10.1158/1078-0432.CCR-10-2203]
15. Gravalos C, Márquez A, García-Carbonero R, Rivera F, Colomer R, Sastre J. Correlation between Her2/neu overexpression/amplification and clinicopathological parameters in advanced gastric cancer patients: a prospective study 2007. Gastrointestinal Cancers Symposium 2007; 130: Abstract 89
16. Leon-Chong J, Lordick F, Kang YK, Park SR, Bang YJ, Sawaki A, Van Cutsem E, Stoss O, Jordan BW, Feyereislova A. HER2 positivity in advanced gastric cancer is comparable to breast cancer - ASCO Annual Meeting Proceedings, Part I. J Clin Oncol 2007; 25 (18S): Abstract 15057. Available from: URL: http://meeting.ascopubs.org/cgi/content/abstract/25/18-suppl/15057
17. Zhang XL, Yang YS, Xu DP, Qu JH, Guo MZ, Gong Y, Huang J. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg 2009; 33: 2112-2118 [PMID: 19636613 DOI: 10.1007/s00268-009-0142-z]
18. Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M, Zamboli A, De Vita F, Galizia G. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 2008; 15: 69-79 [PMID: 17896140]
19. Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, Nakajima TE, Kato K, Hamaguchi T, Shimada Y, Okayama Y, Oka T, Shirao K. Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer 2008; 98: 832-839 [PMID: 18231104 DOI: 10.1038/sj.bjc.6604211]
20. Isinger-Ekstrand A, Johansson J, Ohlsson M, Francis P, Staaf J, Jönsson M, Borg A, Nilbert M. Genetic profiles of gastroesophageal cancer: combined analysis using expression array and tiling array - comparative genomic hybridization. Cancer Genet Cytogenet 2010; 200: 120-126 [PMID: 20620594 DOI: 10.1016/j.cancergencyto.2010.03.01]
21. Janjigian YY, Tang LH, Coit DG, Kelsen DP, Francone TD, Weiser MR, Jhanwar SC, Shah MA. MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 1021-1027 [PMID: 21393565 DOI: 10.1158/1055-9965.EPI-10-1080]
22. Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, Zhang S, Lee M, Wu J, Lim KH, Lei Z, Goh G, Lim QY, Tan AL, Sin Poh DY, Riahi S, Bell S, Shi MM, Linnartz R, Zhu F, Yeoh KG, Toh HC, Yong WP, Cheong HC, Rha SY, Boussioutas A, Grabsch H, Rozen S, Tan P. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 2012; 61: 673-684 [PMID: 22315472 DOI: 10.1136/gutjnl-2011-301839]
23. Kitadai Y, Sasaki A, Ito M, Tanaka S, Oue N, Yasui W, Aihara M, Imagawa K, Haruma K, Chayama K. Helicobacter pylori infection influences expression of genes related to angiogenesis and invasion in human gastric carcinoma cells. Biochem Biophys Res Commun 2003; 311: 809-814 [PMID: 14623253]
24. Wu CY, Wang CJ, Tseng CC, Chen HP, Wu MS, Lin JT, Inoue H, Chen GH. Helicobacter pylori promote gastric cancer cells invasion through a NF-kappaB and COX-2-mediated pathway. World J Gastroenterol 2005; 11: 3197-3203 [PMID: 15929167]
25. Tuccillo C, Cuomo A, Rocco A, Martinelli E, Staibano S, Mascolo M, Gravina AG, Nardone G, Ricci V, Ciardiello F, Del Vecchio Blanco C, Romano M. Vascular endothelial growth factor and neo-angiogenesis in H. pylori gastritis in humans. J Pathol 2005; 207: 277-284 [PMID: 16184519]
26. Carneiro F, Huntsman DG, Smyrk TC, Owen DA, Seruca R, Pharoah P, Caldas C, Sobrinho-Simões M. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 2004; 203: 681-687 [PMID: 15141383]
27. Tamura G, Yin J, Wang S, Fleisher AS, Zou T, Abraham JM, Kong D, Smolinski KN, Wilson KT, James SP, Silverberg SG, Nishizuka S, Terashima M, Motoyama T, Meltzer SJ. E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst 2000; 92: 569-573 [PMID: 10749913]
28. Liu YC, Shen CY, Wu HS, Hsieh TY, Chan DC, Chen CJ, Yu JC, Yu CP, Harn HJ, Chen PJ, Hsieh CB, Chen TW, Hsu HM. Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas. World J Gastroenterol 2006; 12: 2168-2173 [PMID: 16610016]
29. Zhou Y, Li G, Wu J, Zhang Z, Wu Z, Fan P, Hao T, Zhang X, Li M, Zhang F, Li Q, Lu B, Qiao L. Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer. Tumour Biol 2010; 31: 549-558 [PMID: 20563765 DOI: 10.1007/s13277-010-0068-y]
30. Hattori Y, Itoh H, Uchino S, Hosokawa K, Ochiai A, Ino Y, Ishii H, Sakamoto H, Yamaguchi N, Yanagihara K, Hirohashi S, Sugimura T, Terada M. Immunohistochemical detection of K-sam protein in stomach cancer. Clin Cancer Res 1996; 2: 1373-1381 [PMID: 9816310]
31. Kobayashi M, Nagata S, Iwasaki T, Yanagihara K, Saitoh I, Karouji Y, Ihara S, Fukui Y. Dedifferentiation of adenocarcinomas by activation of phosphatidylinositol 3-kinase. Proc Natl Acad Sci USA 1999; 96: 4874-4879 [PMID: 10220386]
32. Murayama T, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, Kawano T, Sugihara K. Relation between outcomes and localisation of p-mTOR expression in gastric cancer. Br J Cancer 2009; 100: 782-788 [PMID: 19223902 DOI: 10.1038/sj.bjc.6604915]
33. Kobayashi M, Iwamatsu A, Shinohara-Kanda A, Ihara S, Fukui Y. Activation of ErbB3-PI3-kinase pathway is correlated with malignant phenotypes of adenocarcinomas. Oncogene 2003; 22: 1294-1301 [PMID: 12618754]
34. Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, Tan SH, Wu J, Lee MH, Ooi CH, Rha SY, Wong WK, Boussioutas A, Yeoh KG, So J, Yong WP, Tsuburaya A, Grabsch H, Toh HC, Rozen S, Cheong JH, Noh SH, Wan WK, Ajani JA, Lee JS, Tellez MS, Tan P. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 2011; 141: 476-85, 485.e1-11 [PMID: 21684283 DOI: 10.1053/j.gastro.2011.04.042]
35. Dulak AM, Schumacher SE, van Lieshout J, Imamura Y, Fox C, Shim B, Ramos AH, Saksena G, Baca SC, Baselga J, Tabernero J, Barretina J, Enzinger PC, Corso G, Roviello F, Lin L, Bandla S, Luketich JD, Pennathur A, Meyerson M, Ogino S, Shivdasani RA, Beer DG, Godfrey TE, Beroukhim R, Bass AJ. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res 2012; 72: 4383-4393 [PMID: 22751462]
36. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996; 77: 858-863 [PMID: 8608475]
37. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676 [PMID: 12778165]
38. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006; 312: 549-560 [PMID: 16336962]
39. Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana CD, Ellis LM. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res 1996; 2: 1679-1684 [PMID: 9816116]
40. Ren J, Dong L, Xu CB, Pan BR. The role of KDR in the interactions between human gastric carcinoma cell and vascular endothelial cell. World J Gastroenterol 2002; 8: 596-601 [PMID: 12174363]
41. Kolev Y, Uetake H, Iida S, Ishikawa T, Kawano T, Sugihara K. Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma. Ann Surg Oncol 2007; 14: 2738-2747 [PMID: 17687613]
42. Shi H, Xu JM, Hu NZ, Xie HJ. Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma. World J Gastroenterol 2003; 9: 1421-1426 [PMID: 12854133]
43. Kim SE, Shim KN, Jung SA, Yoo K, Lee JH. The clinicopathological significance of tissue levels of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in gastric cancer. Gut Liver 2009; 3: 88-94 [PMID: 20431729 DOI: 10.5009/gnl.2009.3.2.88]
44. Song ZJ, Gong P, Wu YE. Relationship between the expression of iNOS,VEGF,tumor angiogenesis and gastric cancer. World J Gastroenterol 2002; 8: 591-595 [PMID: 12174362]
45. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Yanoma S, Noguchi Y. Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett 2000; 153: 7-12 [PMID: 10779624]
46. Karayiannakis AJ, Syrigos KN, Polychronidis A, Zbar A, Kouraklis G, Simopoulos C, Karatzas G. Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg 2002; 236: 37-42 [PMID: 12131083]
47. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004; 7: 335-345 [PMID: 15886877]
48. De Vita F, Giuliani F, Silvestris N, Rossetti S, Pizzolorusso A, Santabarbara G, Galizia G, Colucci G, Ciardiello F, Orditura M. Current status of targeted therapies in advanced gastric cancer. Expert Opin Ther Targets 2012; 16 Suppl 2: S29-S34 [PMID: 22443228 DOI: 10.1517/14728222.2011.652616]
49. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, O'Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, Schwartz GK, Kelsen DP. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24: 5201-5206 [PMID: 17114652]
50. El-Rayes BF, Zalupski M, Bekai-Saab T, Heilbrun LK, Hammad N, Patel B, Urba S, Shields AF, Vaishampayan U, Dawson S, Almhanna K, Smith D, Philip PA. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol 2010; 21: 1999-2004 [PMID: 20332133 DOI: 10.1093/annonc/mdq065]
51. Kang Y, Ohtsu A, van Cutsem E, Rha SY, Sawaki A, Park S, Lim H, Wu J, Langer B, Shah MA. AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cis plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol 2010; 28 (18s): Abstract LBA4007
52. Shah MA, Van Cutsem E, Kang YK, Dakhil SR, Satoh T, Chin K, Bang YJ, Bu L, Bilic G, Ohtsu A. Survival analysis according to disease subtype in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients (pts) with advanced gastric cancer. J Clin Oncol 2012; 30: Abstract 05
53. Kang Y, Ohtsu, A, van Cutsem E, Roman L, Nunes J, Li C, Otero D, Rivera F, Aprile G, Pimentel Alvarez PR, Moehler MH, Wu J, Langer B, Shah MA. Survival analysis by pooling risk factors in AVAGAST: First-line capecitabine plus bevacizumab or placebo in patients with advanced gastric cancer. J Clin Oncol 2011; 29: Abstract 4119
54. Shah M, Kang YK, Ohtsu A, Delmar P, Foernzler D, Langer B, Scherer S, van Cutsem E. Tumor and blood plasma biomarker analyses in the AVAGAST phase III randomized study of first-line bevacizumab capecitabine/cis in patients with advanced gastric cancer. ESMO 2010; Abstract 4675
55. Smyth EC, Langley RE, Stenning SP, Stevenson L, Allum WH, Grabsch H, Alderson D, Riddell AM, Crosby T, Mason R. ST03: A randomized trial of perioperative epirubicin, cis plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with operable gastric, oesophagogastric junction (OGJ) or lower oesophageal adenocarcinoma. J Clin Oncol 2012; 30: Abstract TPS4143
56. Krupitskaya Y, Wakelee HA. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEG-FR-2 for the potential treatment of cancer. Curr Opin Investig Drugs 2009; 10: 597-605 [PMID: 19513949]
57. Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O'Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, Eckhardt SG. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010; 28: 780-787 [PMID: 20048182 DOI: 10.1200/JCO.2009.23.7537]
58. Fuchs CS, Tomasek J, Cho JY, Dumitru F, Passalacqua R, Goswami C, Safran H, Vieira dos Santos L, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Tabernero J, Zalcberg JR, Chau I, Koshiji M, Hsu Y, Schwartz JD, Ajani JA. REGARD: A phase III, randomized, double blind trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or GEJ adenocarcinoma following disease progression on first-line platinum and/or fluoropyrimidine containing combination therapy. GICS 2013. J Clin Oncol 2012; 30: Abstract LBA5
59. Chau I, Passalacqua R. Tolerability and quality-of-life (QoL) results from the phase III REGARD study: Ramucirumab versus placebo in patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma. Eur J Cancer 2011; 47 (Supplement 1): Abstract 2588
60. Wilke H, Van Cutsem E. RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy. J Clin Oncol 2014; 32 (suppl 3): abstr LBA7
61. ClinicalTrials.gov. A study of ramucirumab in patients with gastric, esophageal and gastroesophageal cancer. Available from: URL: http://clinicaltrials.gov/ct2/show/record/NCT01246960
62. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7: 3129-3140 [PMID: 18852116 DOI: 10.1158/1535-7163.MCT-08-0013]
63. Sun W, Powell M, O'Dwyer PJ, Catalano P, Ansari RH, Benson AB. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010; 28: 2947-2951 [PMID: 20458043 DOI: 10.1200/JCO.2009.27.7988]
64. Gallego R, Martin-Richard M, Pericay C, Garcia-Foncillas J, Queralt B, Casado E, Feliu J, Vega I, Juez I, Visa L. Phase II study of oxaliplatin and sorafenib in advanced gastric cancer after failure of cis-fluoropyrimidine-based (PF) treatment. J Clin Oncol 2012; 30: Abstract 4079
65. NCT00565370: Capecitabine and Cisplatin (XP) Sorafenib in Advanced Gastric Cancer (AGC) (XP Sorafenib). Available from: URL: http://clinicaltrial.gov/ct2/show/NCT00565370?term=NCT00565370HYPERLINK
66. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007; 25: 884-896 [PMID: 17327610]
67. Moehler M, Mueller A, Hartmann JT, Ebert MP, Al-Batran SE, Reimer P, Weihrauch M, Lordick F, Trarbach T, Biesterfeld S, Kabisch M, Wachtlin D, Galle PR; German Arbeitsgemeinschaft Internistische Onkologie (AIO). An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer 2011; 47: 1511-1520 [PMID: 21561763 DOI: 10.1016/j.ejca.2011.04.006]
68. Bang YJ, Kang YK, Kang WK, Boku N, Chung HC, Chen JS, Doi T, Sun Y, Shen L, Qin S, Ng WT, Tursi JM, Lechuga MJ, Lu DR, Ruiz-Garcia A, Sobrero A. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs 2011; 29: 1449-1458 [PMID: 20461441 DOI: 10.1007/s10637-010-9438-y]
69. Lindsay CR, MacPherson IR, Cassidy J. Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. Future Oncol 2009; 5: 421-432 [PMID: 19450171 DOI: 10.2217/fon.09.18]
70. Satoh T, Yamada Y, Muro K, Hayashi H, Shimada Y, Takahari D, Taku K, Nakajima TE, Shi X, Brown KH, Boku N. Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer. Cancer Chemother Pharmacol 2012; 69: 439-446 [PMID: 21853311 DOI: 10.1007/s00280-011-1723-8]
71. Tian S, Quan H, Xie C, Guo H, Lü F, Xu Y, Li J, Lou L. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci 2011; 102: 1374-1380 [PMID: 21443688 DOI: 10.1111/j.1349-7006.2011.01939.x]
72. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109 [PMID: 15466206]
73. Li J, Qin S, Xu J, Guo WJ, Xiong JP, Bai Y, Sun G, Yang Y, Wang L, Xu N, Cheng Y, Zhe-Hai W, Zheng L, Tao M. A randomized, double-blind, multicenter, phase II, three-arm, placebo-control study of apatinib as third-line treatment in patients with metastatic gastric carcinoma. J Clin Oncol 2011; 29 (supplement): Abstract 4019
74. Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer. Accessed on 20 November 2012. Available from: URL: http://clinicaltrials.gov/ct2/show/NCT01512745/
75. TEL0805 trial: A phase 2 study of telatinib (TEL) in combination with capecitabine (X) and cis (P) as first-line treatment in patients (pts) with advanced gastric or gastro-esophageal junction (GEJ) cancer. A Study of Telatinib in Combination with Chemotherapy in Subjects With Advanced Gastric Cancer. Available from: URL: http://clinicaltrials.gov/show/NCT00952497/
76. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-1174 [PMID: 18337605 DOI: 10.1056/NEJMra0707704]
77. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-354 [PMID: 15864276]
78. Oda K, Matsuoka Y, Funahashi A, Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 2005; 1: 2005.0010 [PMID: 16729045]
79. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 2008; 52: 738-746 [PMID: 18397279 DOI: 10.1111/j.1365-2559.2008.03021.x]
80. Baselga J. Targeting the epidermal growth factor receptor: a clinical reality. J Clin Oncol 2001; 19: 41S-44S [PMID: 11560970]
81. Nyati MK, Morgan MA, Feng FY, Lawrence TS. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 2006; 6: 876-885 [PMID: 17036041]
82. Lee SH, Lee JW, Soung YH, Kim HS, Park WS, Kim SY, Lee JH, Park JY, Cho YG, Kim CJ, Nam SW, Kim SH, Lee JY, Yoo NJ. BRAF and KRAS mutations in stomach cancer. Oncogene 2003; 22: 6942-6945 [PMID: 14534542]
83. van Grieken NC, Aoyama T, Chambers PA, Bottomley D, Ward LC, Inam I, Buffart TE, Das K, Lim T, Pang B, Zhang SL, Tan IB, Carvalho B, Heideman DA, Miyagi Y, Kameda Y, Arai T, Meijer GA, Tsuburaya A, Tan P, Yoshikawa T, Grabsch HI. KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: results from a large international multicentre study. Br J Cancer 2013; 108: 1495-1501 [PMID: 23511561 DOI: 10.1038/bjc.2013.109]
84. Yokoyama H, Ikehara Y, Kodera Y, Ikehara S, Yatabe Y, Mochizuki Y, Koike M, Fujiwara M, Nakao A, Tatematsu M, Nakanishi H. Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. Br J Cancer 2006; 95: 1504-1513 [PMID: 17088902]
85. Rojo F, Tabernero J, Albanell J, Van Cutsem E, Ohtsu A, Doi T, Koizumi W, Shirao K, Takiuchi H, Ramon y Cajal S, Baselga J. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 2006; 24: 4309-4316 [PMID: 16963731]
86. Rodriguez CP, Adelstein DJ, Rice TW, Rybicki LA, Videtic GM, Saxton JP, Murthy SC, Mason DP, Ives DI. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. J Thorac Oncol 2010; 5: 229-235 [PMID: 20009775 DOI: 10.1097/JTO.0b013e3181c5e334]
87. Anido J, Matar P, Albanell J, Guzmán M, Rojo F, Arribas J, Averbuch S, Baselga J. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 2003; 9: 1274-1283 [PMID: 12684395]
88. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, Neveu M, Pollack VA, Pustilnik LR, Reynolds MM, Sloan D, Theleman A, Miller P. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997; 57: 4838-4848 [PMID: 9354447]
89. Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J, Benedetti JK, Baker AF, Hackett CB, Urba SG, Zaner KS, Blanke CD, Abbruzzese JL. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006; 24: 4922-4927 [PMID: 17050876]
90. Moutinho C, Mateus AR, Milanezi F, Carneiro F, Seruca R, Suriano G. Epidermal growth factor receptor structural alterations in gastric cancer. BMC Cancer 2008; 8: 10 [PMID: 18199332 DOI: 10.1186/1471-2407-8-10]
91. De Vita F, Orditura M, Martinelli E, Vecchione L, Innocenti R, Sileni VC, Pinto C, Di Maio M, Farella A, Troiani T, Morgillo F, Napolitano V, Ancona E, Di Martino N, Ruol A, Galizia G, Del Genio A, Ciardiello F. A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. Br J Cancer 2011; 104: 427-432 [PMID: 21245865 DOI: 10.1038/sj.bjc.6606093]
92. Gold PJ, Goldman B, Iqbal S, Leichman LP, Zhang W, Lenz HJ, Blanke CD. Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415). J Thorac Oncol 2010; 5: 1472-1476 [PMID: 20631636 DOI: 10.1097/JTO.0b013e3181e77a92]
93. Lordick F, Luber B, Lorenzen S, Hegewisch-Becker S, Folprecht G, Wöll E, Decker T, Endlicher E, Röthling N, Schuster T, Keller G, Fend F, Peschel C. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer 2010; 102: 500-505 [PMID: 20068568 DOI: 10.1038/sj.bjc.6605521]
94. Moehler M, Mueller A, Trarbach T, Lordick F, Seufferlein T, Kubicka S, Geissler M, Schwarz S, Galle PR, Kanzler S; German Arbeitsgemeinschaft Internistische Onkologie. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Ann Oncol 2011; 22: 1358-1366 [PMID: 21119032 DOI: 10.1093/annonc/mdq591]
95. Pinto C, Di Fabio F, Barone C, Siena S, Falcone A, Cascinu S, Rojas Llimpe FL, Stella G, Schinzari G, Artale S, Mutri V, Giaquinta S, Giannetta L, Bardelli A, Martoni AA. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer 2009; 101: 1261-1268 [PMID: 19773760 DOI: 10.1038/sj.bjc.6605319]
96. Richards D, Kocs DM, Spira AI, David McCollum A, Diab S, Hecker LI, Cohn A, Zhan F, Asmar L. Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study. Eur J Cancer 2013; 49: 2823-2831 [PMID: 23747051 DOI: 10.1016/j.ejca.2013.04.022]
97. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Götte H, Melezínková H, Moehler M; Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 14: 490-499 [PMID: 23594786 DOI: 10.1016/S1470-2045(13)70102-5]
98. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-4705 [PMID: 20921465 DOI: 10.1200/JCO.2009.27]
99. Peeters M, Hotko YS, Cervantes-Ruiperez A, Ducreux M, Andre T, Strickland A, Wilson G, Tian Y, Gansert JL. Randomized phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Patient reported outcomes (PRO). Orlando, FL: Presented at 2010 Gastrointestinal Cancers Symposium, 2010: Abstract 282
100. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634 [PMID: 18316791 DOI: 10.1200/JCO.2007.14.7116]
101. Okines AF, Ashley SE, Cunningham D, Oates J, Turner A, Webb J, Saffery C, Chua YJ, Chau I. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol 2010; 28: 3945-3950 [PMID: 20679619 DOI: 10.1200/JCO.2010.29.2847]
102. Chau I, Okines AFC, González de Castro D, Saffery C, Barbachano Y, Wotherspoon L, Puckey L, Hulkki Wilson S, Coxon FY, Middleton GW. REAL3: A multicentre randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer. Response rate (RR), toxicity, and molecular analysis from phase II. J Clin Oncol 2011; 29: Abstract 4131
103. Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, Ferry D, Mansoor W, Crosby T, Coxon F, Smith D, Waters J, Iveson T, Falk S, Slater S, Peckitt C, Barbachano Y. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 14: 481-489 [PMID: 23594787 DOI: 10.1016/S1470-2045(13)70096-2]
104. NCT01379807. Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (SPIGA). Available from: URL: http://clinicaltrial.gov/ct2/show/study/NCT01379807?term=panitumumabgastriccancerHYPERLINK
105. Lo KM, Lan Y, Zhang X. The role of ADCC effector function in the anti-tumor efficacy of anti-EGFR antibodies in a mouse xenograft model. AACR-NCI-EORTC. Int Conf Mol Targets Cancer Ther 2003; Abstract A123
106. Burger AM, Heiss NS, Kreysch HG. The humanized monoclonal anti-EGFR antibody EMD72000 potently inhibits the growth of EGFR-expressing human tumor xenografts insensitive to chemotherapeutic drugs. Proc Am Assoc Cancer Res 2003; 44: Abstract 5719
107. Rao S, Starling N, Cunningham D, Benson M, Wotherspoon A, Lüpfert C, Kurek R, Oates J, Baselga J, Hill A. Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br J Cancer 2008; 99: 868-874 [PMID: 19238629 DOI: 10.1038/sj.bjc.6604622]
108. Spicer J. Technology evaluation: nimotuzumab, the Center of Molecular Immunology/YM BioSciences/Oncoscience. Curr Opin Mol Ther 2005; 7: 182-191 [PMID: 15844627]
109. Crombet T, Torres L, Neninger E, Catalá M, Solano ME, Perera A, Torres O, Iznaga N, Torres F, Pérez R, Lage A. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother 2003; 26: 139-148 [PMID: 12616105]
110. Brade AM, Magalhaes J, Siu L, Oza A, Lovell S, de Borja M, Pond G, Sherman I, Hedley D, Chen E. A single agent, phase I pharmacodynamic study of nimotuzumab (TheraCIM-h-R3) in patients with advanced refractory solid tumors. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; 25 (18S): Abstract 14030
111. Kim YH, Sasaki Y, Lee KH, Rha SY, Park S, Boku N, Komatsu Y, Kim T, Kim S, Sakata Y. Randomized phase II study of nimotuzumab, an anti-EGFR antibody, plus iri in patients with 5-fluorouracil-based regimen-refractory advanced or recurrent gastric cancer in Korea and Japan: Preliminary results. J Clin Oncol 2011; 29: Abstract 87
112. Wang JW, Chi Y, Zheng Z, Qu T, Zhou A, Yang L, Jiang W, Shi S, Sun Y, Song Y, Kang S. Randomized, single-centered, phase II clinical trial of nimotuzumab plus cis and S-1 as first-line therapy in patients with advanced gastric cancer. J Clin Oncol 2012; 30: Abstract e14668
113. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792 [PMID: 11248153]
114. Cidon EU, Centeno RG, Lagarto EG, Peral JI. HER-2 Evaluation in a Specific Gastric Cancer Population with the Highest Rate of Mortality in Spain. J Oncol 2011; 2011: 391564 [PMID: 22131990 DOI: 10.1155/2011/391564]
115. Begnami MD, Fukuda E, Fregnani JH, Nonogaki S, Montagnini AL, da Costa WL, Soares FA. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol 2011; 29: 3030-3036 [PMID: 21709195 DOI: 10.1200/JCO.2010.33.6313]
116. Grabsch H, Sivakumar S, Gray S, Gabbert HE, Müller W. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol 2010; 32: 57-65 [PMID: 20208134 DOI: 10.3233/CLO-2009-0497]
117. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52: 797-805 [PMID: 18422971 DOI: 10.1111/j.1365-2559.2008.03028.x]
118. Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, Shah MA, Al-Batran SE. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 2012; 23: 2656-2662 [PMID: 22689179]
119. De Vita F, Giuliani F, Silvestris N, Catalano G, Ciardiello F, Orditura M. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treat Rev 2010; 36 Suppl 3: S11-S15 [PMID: 21129604 DOI: 10.1016/S0305-7372(10)70014-1]
120. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999; 26: 60-70 [PMID: 10482195]
121. Cortés-Funes H, Rivera F, Alés I, Márquez A, Velasco A, Colomer R, García-Carbonero R, Sastre J, Guerra J, Grávalos C. Phase II of T and cis in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification. J Clin Oncol 2007; 25: Abstract 4613
122. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697 [PMID: 20728210 DOI: 10.1016/S0140-6736(10)61121-X]
123. Rech J, Arnold D, Folprecht G. A pilot study of trastuzumab monotherapy in patients whoprogressed while on chemotherapy for metastatic or locally advanced HER-2 positive gastric cancer. ESMO 2006; 17: 314 (Abstract 1096)
124. NCT01450696. HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer. Available from: URL: http://clinicaltrials.gov/show/NCT01450696
125. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68: 9280-9290 [PMID: 19010901 DOI: 10.1158/0008-5472.CAN-08-1776]
126. NCT01641939. A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric. Available from: URL: http://clinicaltrials.gov/show/NCT01641939
127. Iqbal S, Goldman B, Lenz HJ, Fenoglio-Preiser CM, Blanke CD. S0413: A phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer. J Clin Oncol 2007; 25: Abstract 4621
128. Galsky MD, Von Hoff DD, Neubauer M, Anderson T, Fleming M, Nagarwala Y, Mahoney JM, Midwinter D, Vocila L, Zaks TZ. Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Invest New Drugs 2012; 30: 695-701 [PMID: 20857170 DOI: 10.1007/s10637-010-9541-0]
129. NCT00680901, LOGiC-Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib. Available from: URL: http://clinicaltrials.gov/ct2/show/NCT00680901?term=LOGiC&rank=8/
130. Satoh T, Bang Y, Wang J, Xu J, Chung HC, Yeh K, Chen J, Mukaiyama A, Yoshida P, Ohtsu A. Interim safety analysis from TYTAN: A phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer. J Clin Oncol 2010; 28: Abstract 4057
131. Yamashita-Kashima Y, Iijima S, Yorozu K, Furugaki K, Kurasawa M, Ohta M, Fujimoto-Ouchi K. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res 2011; 17: 5060-5070 [PMID: 21700765 DOI: 10.1158/1078-0432.CCR-10-2927]
132. Kang YK, Rha SY, Tassone P, Barriuso J, Yu R, Szado T, Garg A, Bang Y. Pertuzumab Pharmacokinetics And Safety In Combination With Trastuzumab And Chemotherapy In Patients With Her2-Positive Advanced Gastric Cancer (Agc). Ann Oncol 2013; 24 (suppl 4): Iv19
133. NCT01774786. A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer. Available from: URL: http://clinicaltrials.gov/show/NCT01774786
134. Shitara K, Doi T, Ohtsu A. Molecular Targeting Therapy and Biomarker for Advanced Gastric Cancer. J Phys Chem Biophys 2012; 2: 1-6 [DOI: 10.4172/2161-0398.100010]
135. Markman B, Atzori F, Pérez-García J, Tabernero J, Baselga J. Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol 2010; 21: 683-691 [PMID: 19713247 DOI: 10.1093/annonc/mdp347]
136. Cidon EU, Ellis SG, Inam Y, Adeleke S, Zarif S, Geldart T. Molecular targeted agents for gastric cancer: a step forward towards personalized therapy. Cancers (Basel) 2013; 5: 64-91 [PMID: 24216699 DOI: 10.3390/cancers5010064]
137. Doi T, Muro K, Boku N, Yamada Y, Nishina T, Takiuchi H, Komatsu Y, Hamamoto Y, Ohno N, Fujita Y, Robson M, Ohtsu A. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 2010; 28: 1904-1910 [PMID: 20231677 DOI: 10.1200/JCO.2009.26.2923]
138. Van Cutsem E, Yeh KH, Bang YJ, Shen L, Ajani JA, Bai YX, Chung HC, Pan HM, Chin K, Muro K, Kim YH, Smith H, Costantini C, Musalli S, Rizvi S, Sahmoud T, Ohtsu A. Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1. J Clin Oncol 2012; 30 (suppl 4): Abstract LBA3
139. NCT01248403. A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy (AIO-STO-0111). Available from: URL: http://clinicaltrials.gov/show/NCT01248403
140. Werner D, Atmaca A, Pauligk C, Pustowka A, Jäger E, Al-Batran SE. Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma. Cancer Med 2013; 2: 325-333 [PMID: 23930209 DOI: 10.1002/cam4.77]
141. Appleman LJ . MET signaling pathway: a rational target for cancer therapy. J Clin Oncol 2011; 29: 4837-4838 [PMID: 22042966 DOI: 10.1200/JCO.2011.37.7929]
142. Sierra JR, Tsao MS. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol 2011; 3: S21-S35 [PMID: 22128285 DOI: 10.1177/1758834011422557]
143. Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, D'Emidio S, Catalano V, Sisti V, Ligorio C, Andreoni F, Rulli E, Di Oto E, Fiorentini G, Zingaretti C, De Nictolis M, Cappuzzo F, Magnani M. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 2011; 29: 4789-4795 [PMID: 22042954 DOI: 10.1200/JCO.2011.36.7706]
144. Lee J, Seo JW, Jun HJ, Ki CS, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS, Noh JH, Kim S, Jang HL, Kim JY, Kim KM, Kang WK, Park JO. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 2011; 25: 1517-1524 [PMID: 21424128 DOI: 10.3892/or.2011.1219]
145. Hara T, Ooi A, Kobayashi M, Mai M, Yanagihara K, Nakanishi I. Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab Invest 1998; 78: 1143-1153 [PMID: 9759658]
146. Tsugawa K, Yonemura Y, Hirono Y, Fushida S, Kaji M, Miwa K, Miyazaki I, Yamamoto H. Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology 1998; 55: 475-481 [PMID: 9732228]
147. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T, Nakano H. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999; 85: 1894-1902 [PMID: 10223227]
148. Huang TJ, Wang JY, Lin SR, Lian ST, Hsieh JS. Overexpression of the c-met protooncogene in human gastric carcinoma - correlation to clinical features. Acta Oncol 2001; 40: 638-643 [PMID: 11669338]
149. Amemiya H, Kono K, Itakura J, Tang RF, Takahashi A, An FQ, Kamei S, Iizuka H, Fujii H, Matsumoto Y. c-Met expression in gastric cancer with liver metastasis. Oncology 2002; 63: 286-296 [PMID: 12381909]
150. Zhao J, Zhang X, Xin Y. Up-regulated expression of Ezrin and c-Met proteins are related to the metastasis and prognosis of gastric carcinomas. Histol Histopathol 2011; 26: 1111-1120 [PMID: 21751142]
151. Cho H, Zhang X, Jung M, Kwon W, Jung J, Jeung H, Roh JH, Chung HC, Rha SH. C-met as a therapeutic target for metastatic potential of gastric cancer. J Clin Oncol 2010; 28: Abstract e14568
152. Jhawer M, Kindler HL, Wainberg Z, Ford J, Kunz P, Tang L, McCallum S, Kallender H, Shah MA. Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study. J Clin Oncol 2009; 27: Abstract 14502
153. Muro K, Ryu MH, Yasui H, Nishina T, Ryoo BY, Boku N, Kang YK. A phase II study of tivantinib monotherapy in patients with previously treated advanced or recurrent gastric cancer. J Clin Oncol 2012; 30: Abstract 4082
154. Okamoto W, Okamoto I, Arao T, Kuwata K, Hatashita E, Yamaguchi H, Sakai K, Yanagihara K, Nishio K, Nakagawa K. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther 2012; 11: 1557-1564 [PMID: 22729845 DOI: 10.1158/1535-7163.MCT-11-0934]
155. Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang YJ, Clark JW, Solomon BJ, Iafrate AJ. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011; 29: 4803-4810 [PMID: 22042947 DOI: 10.1200/JCO.2011.35.4928]
156. Cao B, Su Y, Oskarsson M, Zhao P, Kort EJ, Fisher RJ, Wang LM, Vande Woude GF. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci USA 2001; 98: 7443-7448 [PMID: 11416216]
157. Gao CF, Xie Q, Zhang YW, Su Y, Zhao P, Cao B, Furge K, Sun J, Rex K, Osgood T, Coxon A, Burgess TL, Vande Woude GF. Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor: c-Met-driven models of leiomyosarcoma. Mol Cancer Ther 2009; 8: 2803-2810 [PMID: 19825800 DOI: 10.1158/1535-7163.MCT-09-0125]
158. Gordon MS, Sweeney CS, Mendelson DS, Eckhardt SG, Anderson A, Beaupre DM, Branstetter D, Burgess TL, Coxon A, Deng H, Kaplan-Lefko P, Leitch IM, Oliner KS, Yan L, Zhu M, Gore L. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factorneutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res 2010; 16: 699-710 [PMID: 20068101 DOI: 10.1158/1078-0432.CCR-09-1365]
159. Iveson T, Donehower RC, Davidenko I, Tjulandin S, Deptala A, Harrison M, Loh E, Jiang Y, Oliner K, Dubey S. Safety and Efficacy of Epirubicin, Cis, and Capecitabine (ECX) Plus Rilotumumab (R) as First-line Treatment for Unresectable Locally Advanced (LA) or Metastatic (M) Gastric or Esophagogastric Junction (EGJ) Adenocarcinoma. ESMO 2011; Abstract 6504
160. NCT01697072. First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma (RILOMET-1). Available from: URL: http://clinicaltrials.gov/ct2/show/NCT01697072?term=RILOMET&rank=1
161. A study of Onartuzumab (MetMab) in combination with mFOLFOX6 in patients with metastatic HER2-negative and MET-positive gastroesophageal cancer (NCT01662869). Available from: URL: http://clinicaltrials.gov/ct2/show/NCT01662869?term=NCT01662869HYPERLINK
162. Itoh N, Ornitz DM. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem 2011; 149: 121-130 [PMID: 20940169 DOI: 10.1093/jb/mvq121]
163. Trueb B. Biology of FGFRL1, the fifth fibroblast growth factor receptor. Cell Mol Life Sci 2011; 68: 951-964 [PMID: 21080029 DOI: 10.1007/s00018-010-0576-3]
164. Tiong KH, Mah LY, Leong CO. Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers. Apoptosis 2013; 18: 1447-1468 [PMID: 23900974]
165. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 10: 116-129 [PMID: 20094046 DOI: 10.1038/nrc2780]
166. Matsumoto K, Arao T, Hamaguchi T, Shimada Y, Kato K, Oda I, Taniguchi H, Koizumi F, Yanagihara K, Sasaki H, Nishio K, Yamada Y. FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer 2012; 106: 727-732 [PMID: 22240789 DOI: 10.1038/bjc.2011.603]
167. Itoh H, Hattori Y, Sakamoto H, Ishii H, Kishi T, Sasaki H, Yoshida T, Koono M, Sugimura T, Terada M. Preferential alternative splicing in cancer generates a K-sam messenger RNA with higher transforming activity. Cancer Res 1994; 54: 3237-3241 [PMID: 8205545]
168. Moffa AB, Tannheimer SL, Ethier SP. Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. Mol Cancer Res 2004; 2: 643-652 [PMID: 15561780]
169. Grose R, Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 2005; 16: 179-186 [PMID: 15863033]
170. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 2006; 281: 15694-15700 [PMID: 16597617]
171. Rand V, Huang J, Stockwell T, Ferriera S, Buzko O, Levy S, Busam D, Li K, Edwards JB, Eberhart C, Murphy KM, Tsiamouri A, Beeson K, Simpson AJ, Venter JC, Riggins GJ, Strausberg RL. Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci USA 2005; 102: 14344-14349 [PMID: 16186508]
172. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009; 8: 235-253 [PMID: 19247306 DOI: 10.1038/nrd2792]
173. Courjal F, Cuny M, Simony-Lafontaine J, Louason G, Speiser P, Zeillinger R, Rodriguez C, Theillet C. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res 1997; 57: 4360-4367 [PMID: 9331099]
174. Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C, Nicoletti R, Winckler W, Grewal R, Hanna M, Wyhs N, Ziaugra L, Richter DJ, Trovik J, Engelsen IB, Stefansson IM, Fennell T, Cibulskis K, Zody MC, Akslen LA, Gabriel S, Wong KK, Sellers WR, Meyerson M, Greulich H. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA 2008; 105: 8713-8717 [PMID: 18552176 DOI: 10.1073/pnas.0803379105]
175. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, Radvanyi F. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999; 23: 18-20 [PMID: 10471491]
176. Jung EJ, Jung EJ, Min SY, Kim MA, Kim WH. Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma. Hum Pathol 2012; 43: 1559-1566 [PMID: 22440694 DOI: 10.1016/j.humpath.2011.12.002]
177. Takeda M, Arao T, Yokote H, Komatsu T, Yanagihara K, Sasaki H, Yamada Y, Tamura T, Fukuoka K, Kimura H, Saijo N, Nishio K. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin Cancer Res 2007; 13: 3051-3057 [PMID: 17505008 DOI: 10.1158/1078-0432.CCR-06-2743]
178. Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A, Elbi C, Lutterbach B. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 2008; 68: 2340-2348 [PMID: 18381441 DOI: 10.1158/0008-5472.CAN-07-5229]
179. Nakamura K, Yashiro M, Matsuoka T, Tendo M, Shimizu T, Miwa A, Hirakawa K. A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer. Gastroenterology 2006; 131: 1530-1541 [PMID: 17101326]
180. Gozgit JM, Wong MJ, Moran L, Wardwell S, Mohemmad QK, Narasimhan NI, Shakespeare WC, Wang F, Clackson T, Rivera VM. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther 2012; 11: 690-699 [PMID: 22238366 DOI: 10.1158/1535-7163.MCT-11-0450]
181. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, Reece D, Heise C, Stewart AK. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4; 14) multiple myeloma. Blood 2005; 105: 2941-2948 [PMID: 15598814]
182. Lee SH, Lopes de Menezes D, Vora J, Harris A, Ye H, Nordahl L, Garrett E, Samara E, Aukerman SL, Gelb AB, Heise C. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 2005; 11: 3633-3641 [PMID: 15897558]
183. Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X, Xu Y, Gao Z, Liu K, Zhou M, Gao B, Shen D, Zhang L, Ji J, Gavine PR, Zhang J, Kilgour E, Zhang X, Ji Q. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res 2013; 19: 2572-2583 [PMID: 23493349 DOI: 10.1158/1078-0432.CCR-12-3898]
184. Clinicaltrials.gov NCT01457846: "Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastrooesophageal Junction Cancer Patients (SHINE). Available from: URL: http://clinicaltrials.gov/ct2/results?term=NCT01457846HYPERLINK
185. Eto K, Iwatsuki M, Watanabe M, Ida S, Ishimoto T, Iwagami S, Baba Y, Sakamoto Y, Miyamoto Y, Yoshida N, Baba H. The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab. Ann Surg Oncol 2014; 21: 343-350 [PMID: 24154840]
186. Chen CT, Kim H, Liska D, Gao S, Christensen JG, Weiser MR. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. Mol Cancer Ther 2012; 11: 660-669 [PMID: 22238368 DOI: 10.1158/1535-7163.MCT-11-0754]
187. Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C, Mutri V, Giannetta L, Giaquinta S, Funaioli C, Berardi R, Longobardi C, Piana E, Martoni AA. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007; 18: 510-517 [PMID: 17164226]
188. Zhang X, Xu J, Shen L, Wang J, Liang J, Xu N, Bai Y, Wang J. A phase II study of cetuximab with cis and capecitabine as first-line treatment in advanced gastric cancer. J Clin Oncol 2008; 26: Abstract 15663
189. Kim C, Lee JL, Ryu MH, Chang HM, Kim TW, Lim HY, Kang HJ, Park YS, Ryoo BY, Kang YK. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest New Drugs 2011; 29: 366-373 [PMID: 19997960 DOI: 10.1007/s10637-009-9363-0]
190. Rao S, Starling N, Cunningham D, Sumpter K, Gilligan D, Ruhstaller T, Valladares-Ayerbes M, Wilke H, Archer C, Kurek R, Beadman C, Oates J. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Ann Oncol 2010; 21: 2213-2219 [PMID: 20497967 DOI: 10.1093/annonc/mdq247]